Zimbabwe's U.S.-supported health programs are due to end on September 30, 2026, after Harare declined the proposed bilateral health agreement. The decision behind the end of U.S. health funding in Zimbabwe is settled, but the financing problem it leaves behind is not.
Zimbabwe's health financing is not starting from zero. The country already has the AIDS Levy, Global Fund programs, Treasury allocations, and earmarked health taxes, while WHO says work on a National Health Financing Strategy is ongoing in 2026, and support for a National Health Insurance Bill runs through 2028.
The harder issue is whether those channels can carry the same services at the same time. Zimbabwe's national health financing policy has long aimed at stronger domestic funding, but replacing a donor is not simply a matter of finding an equal dollar figure because medicines, staff support, prevention programs, procurement, and clinic operations can sit in different funding streams.
The Global Fund is another major layer. A July 2026 UNDP report on Zimbabwe's 2025 grant year said 1,230,298 adults and children were receiving antiretroviral therapy by the end of 2025, while the HIV grant's approved budget for the 2024 to 2026 cycle was about $181.8 million. PEPFAR funding in Zimbabwe has supported part of the wider response, but Global Fund financing and domestic revenue are separate channels rather than one interchangeable pot of money.
Zimbabwe HIV prevention also now includes twice-yearly lenacapavir, which began rolling out in 2026 with U.S. and Global Fund backing. The National AIDS Council said the initial Zimbabwe rollout targeted more than 46,000 people at 24 sites, and the Global Fund says the country was among the early African adopters already administering the drug by April. Keeping a newer prevention program financed is a different problem from maintaining a mature antiretroviral supply chain.
Zimbabwe health insurance and Zimbabwe universal health coverage are longer-term pooling questions, not instant replacement cash. WHO's 2026 monitoring shows active work on a new health financing strategy and continuing support for development of a National Health Insurance Bill through 2028. Those reforms may change how money is collected and pooled, but they do not by themselves replace contracts or services ending this month.
Zimbabwe's political economy of health financing reforms matters here because financing rules shift responsibilities among taxpayers, government, donors, insurers, providers, and patients. A major review found that Zimbabwe's recurring problem has been less about identifying possible reforms and more about turning them into durable institutions that can actually implement them.
The Zimbabwe HIV epidemic is also far enough along that a single Zimbabwe HIV infection rate says little about financing resilience. The percentage of Zimbabwe's population living with HIV is useful for measuring burden, but service continuity depends on testing, treatment retention, viral suppression, prevention access, and the systems underneath them. UNDP reported 94.95 percent ART coverage across adults and children living with HIV at the end of 2025, which makes preserving continuity more important than merely protecting one procurement line.
How much Zimbabwe spends on healthcare matters, but timing and allocation matter just as much. A budget increase can arrive after a contract expires, an earmarked levy can be legally unavailable for another program, and a national insurance scheme can take years to build. Zimbabwe's health financing strategy therefore has to solve a coordination problem as much as a revenue problem.
For now, the Zimbabwe healthcare system still has domestic revenue mechanisms and active Global Fund support, but neither should be treated as a one-for-one substitute for the U.S. programs ending in September. The practical measure is whether treatment, prevention, staffing, procurement, and financing remain connected through the handover without shifting more of the burden onto patients.
Zimbabwe's health financing is not starting from zero. The country already has the AIDS Levy, Global Fund programs, Treasury allocations, and earmarked health taxes, while WHO says work on a National Health Financing Strategy is ongoing in 2026, and support for a National Health Insurance Bill runs through 2028.
The harder issue is whether those channels can carry the same services at the same time. Zimbabwe's national health financing policy has long aimed at stronger domestic funding, but replacing a donor is not simply a matter of finding an equal dollar figure because medicines, staff support, prevention programs, procurement, and clinic operations can sit in different funding streams.
Domestic money can protect treatment before it replaces aid
The AIDS Levy is the clearest domestic instrument. ZIMRA currently lists the levy at 3 percent of income tax chargeable, while the AIDS Levy trust fund remains part of the government's plan for financing HIV services. The distinction matters because the levy is not simply 3 percent of gross income or company revenue.The Global Fund is another major layer. A July 2026 UNDP report on Zimbabwe's 2025 grant year said 1,230,298 adults and children were receiving antiretroviral therapy by the end of 2025, while the HIV grant's approved budget for the 2024 to 2026 cycle was about $181.8 million. PEPFAR funding in Zimbabwe has supported part of the wider response, but Global Fund financing and domestic revenue are separate channels rather than one interchangeable pot of money.
Zimbabwe HIV prevention also now includes twice-yearly lenacapavir, which began rolling out in 2026 with U.S. and Global Fund backing. The National AIDS Council said the initial Zimbabwe rollout targeted more than 46,000 people at 24 sites, and the Global Fund says the country was among the early African adopters already administering the drug by April. Keeping a newer prevention program financed is a different problem from maintaining a mature antiretroviral supply chain.
Not every health levy can fill the same gap
The phrase Zimbabwe health expenditure can hide a basic accounting problem. Money raised for one health purpose is not automatically available for another, and sugar levy proceeds have already been used for cancer equipment while Parliament and the Health Ministry continue debating stronger legal ring-fencing for health taxes. They cannot simply be counted as a general replacement fund for HIV services.Zimbabwe health insurance and Zimbabwe universal health coverage are longer-term pooling questions, not instant replacement cash. WHO's 2026 monitoring shows active work on a new health financing strategy and continuing support for development of a National Health Insurance Bill through 2028. Those reforms may change how money is collected and pooled, but they do not by themselves replace contracts or services ending this month.
Zimbabwe's political economy of health financing reforms matters here because financing rules shift responsibilities among taxpayers, government, donors, insurers, providers, and patients. A major review found that Zimbabwe's recurring problem has been less about identifying possible reforms and more about turning them into durable institutions that can actually implement them.
The real test is continuity across services
A Zimbabwe health crisis would not be measured only by antiretroviral stockouts. The U.S. role has included HIV treatment and prevention, health-worker support, condoms, family planning, and wider public-health functions, so a smooth handover has to keep several pieces moving at once.The Zimbabwe HIV epidemic is also far enough along that a single Zimbabwe HIV infection rate says little about financing resilience. The percentage of Zimbabwe's population living with HIV is useful for measuring burden, but service continuity depends on testing, treatment retention, viral suppression, prevention access, and the systems underneath them. UNDP reported 94.95 percent ART coverage across adults and children living with HIV at the end of 2025, which makes preserving continuity more important than merely protecting one procurement line.
How much Zimbabwe spends on healthcare matters, but timing and allocation matter just as much. A budget increase can arrive after a contract expires, an earmarked levy can be legally unavailable for another program, and a national insurance scheme can take years to build. Zimbabwe's health financing strategy therefore has to solve a coordination problem as much as a revenue problem.
For now, the Zimbabwe healthcare system still has domestic revenue mechanisms and active Global Fund support, but neither should be treated as a one-for-one substitute for the U.S. programs ending in September. The practical measure is whether treatment, prevention, staffing, procurement, and financing remain connected through the handover without shifting more of the burden onto patients.
